Vanesa-Sindi Ivanova, Thomas Menter, Ningxuan Cui, Peter Leary, Carl Zinner, Jörg P. Halter, Frank Stenner, Stefan Dirnhofer, Anne Müller, Alexandar Tzankov
{"title":"Distinct subtypes of post-transplant lymphoproliferative disorders: CHIP-like mutations in early lesions and substantial mutational differences between EBV-positive and EBV-negative diffuse large B-cell lymphomas","authors":"Vanesa-Sindi Ivanova, Thomas Menter, Ningxuan Cui, Peter Leary, Carl Zinner, Jörg P. Halter, Frank Stenner, Stefan Dirnhofer, Anne Müller, Alexandar Tzankov","doi":"10.1111/bjh.19952","DOIUrl":"10.1111/bjh.19952","url":null,"abstract":"<div>\u0000 \u0000 <p>Post-transplant lymphoproliferative disorders (PTLD) and lymphomas in immunocompromised individuals represent significant clinical challenges, with a limited understanding of their pathogenesis. We investigated a PTLD cohort (<i>n</i> = 50) consisting of ‘early lesions’ (infectious mononucleosis-like PTLD, plasmacytic and follicular hyperplasias), polymorphic PTLD and post-transplant diffuse large B-cell lymphomas (PT-DLBCL). The study also included 15 DLBCL with autoimmune/immunocompromised backgrounds (IS-DLBCL) and 14 DLBCL, not otherwise specified (DLBCL, NOS), as control. To investigate microarchitectural and genetic changes, immunohistochemistry, multiplex immunofluorescence (mIF), fluorescence <i>in situ</i> hybridisation and high-throughput sequencing were performed. Scarcity of viral infections other than Epstein–Barr virus (EBV) was observed. mIF revealed lower Treg infiltration in PT-DLBCL and high CD8<sup>+</sup>/PD1<sup>+</sup> T cells in IS-DLBCL. <i>MYC</i> rearrangements were most common in PT-DLBCL, followed by IS-DLBCL and DLBCL, NOS, all EBV-negative. <i>TP53</i> mutations were frequent in EBV-negative PT-DLBCL and DLBCL, NOS but absent in ‘early lesions’. <i>NOTCH1</i> mutations were predominant in PT-DLBCL (N1 DLBCL-subgroup). Gene expression profiling showed a significant overlap between ‘early lesions’ and polymorphic PTLD. The presence of clonal haematopoiesis of indeterminate potential (CHIP)-like mutations and the absence of immune-escape gene mutations in ‘early lesions’ suggest these disorders may represent clonal expansions driven by exogenic immunosuppression and/or EBV infection ‘substituting’ for mutations of the latter group of genes.</p>\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 2","pages":"484-504"},"PeriodicalIF":5.1,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lamya Garabet, Anbjørg Rangberg, Anna Maria Eriksson, Christine Monceyron Jonassen, Raul Teruel-Montoya, Maria Luisa Lozano, Constantino Martinez, Heidi Hassel Pettersen, Åse-Berit Mathisen, Eirik Tjønnfjord, Hoa Tran, Ellen Brodin, Galina Tsykunova, Johanna Gebhart, James Bussel, Waleed Ghanima
{"title":"MicroRNA-199a-5p may be a diagnostic biomarker of primary ITP.","authors":"Lamya Garabet, Anbjørg Rangberg, Anna Maria Eriksson, Christine Monceyron Jonassen, Raul Teruel-Montoya, Maria Luisa Lozano, Constantino Martinez, Heidi Hassel Pettersen, Åse-Berit Mathisen, Eirik Tjønnfjord, Hoa Tran, Ellen Brodin, Galina Tsykunova, Johanna Gebhart, James Bussel, Waleed Ghanima","doi":"10.1111/bjh.19987","DOIUrl":"https://doi.org/10.1111/bjh.19987","url":null,"abstract":"<p><p>There is no diagnostic test for primary immune thrombocytopenia (ITP). Certain microRNAs have shown to have diagnostic potential in ITP. We validated 12 microRNAs identified from two previous studies to find a diagnostic biomarker. The study included two ITP cohorts (n = 61) and healthy controls (n = 28). The first ITP cohort involved 24 patients from the Prolong study, patients with newly diagnosed/persistent ITP (<1 year) treated with corticosteroids ± IVIG but relapsed/failed to respond. The second cohort comprised 37 patients from ITP biobank, Østfold Hospital, Norway, patients had different disease stages and therapies. Twelve microRNAs were measured: miR-199a-5p, miR-33a-5p, miR-195-5p, miR-130a-3p, miR-144-3p, miR-146a-5p, miR-222-3p, miR-374b-5p, miR-486-5p, miR-1341-5p, miR-766-3p and miR-409-3p. miR-199a-5p, miR-33a-5p, miR-374b-5p, miR-146a-5p and miR-409-3p were expressed differentially in the entire ITP cohort compared to controls; of those only miR-199a-5p showed good discriminative ability between ITP and controls with area under the curve (AUC) of 0.718 (95% CI: 0.599-0.836). In the Prolong cohort (ITP < 1 year), miR-199a-5p and miR-374b-5p showed very good discriminative ability between ITP and controls with AUC of 0.824 (0.708-0.940) and 0.806 (0.688-0.924) respectively. This study confirmed that miR-199a-5p has good discriminative ability between primary ITP and healthy controls, thus may be a diagnostic biomarker of ITP.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jennifer Pinney, Candice Roufosse, Andreas Kousios, Aristeidis Chaidos, Julian D. Gillmore, Francesco Rainone, Satarupa Choudhuri, Karthik Ramasamy, Sarah Blakey, John Ashcroft, Y. L. Tracey Chan, Paul Cockwell, Guy Pratt, the BSH Committee
{"title":"Diagnosis and management of monoclonal gammopathy of renal significance: A British Society for Haematology good practice paper","authors":"Jennifer Pinney, Candice Roufosse, Andreas Kousios, Aristeidis Chaidos, Julian D. Gillmore, Francesco Rainone, Satarupa Choudhuri, Karthik Ramasamy, Sarah Blakey, John Ashcroft, Y. L. Tracey Chan, Paul Cockwell, Guy Pratt, the BSH Committee","doi":"10.1111/bjh.19956","DOIUrl":"10.1111/bjh.19956","url":null,"abstract":"<p>This guideline provides consensus opinion on the investigations required for people presenting with suspected monoclonal gammopathy of renal significance to both nephrology and haematology physicians. The guideline discusses the principles of treating a patient with MGRS and provides recommendations for both supportive management and haematological therapy. It details the recommended on-going monitoring required for both specialty areas.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 2","pages":"447-463"},"PeriodicalIF":5.1,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19956","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesca Perutelli, Elia Boccellato, Maria Chiara Montalbano, Gioacchino Catania, Marina Deodato, Anna Maria Frustaci, Idanna Innocenti, Riccardo Moia, Francesca Maria Quaglia, Giulia Quaresmini, Paolo Rivela, Gianluca Gaidano, Mauro Krampera, Luca Laurenti, Alessandro Rambaldi, Benedetto Bruno, Candida Vitale, Marta Coscia
{"title":"Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation","authors":"Francesca Perutelli, Elia Boccellato, Maria Chiara Montalbano, Gioacchino Catania, Marina Deodato, Anna Maria Frustaci, Idanna Innocenti, Riccardo Moia, Francesca Maria Quaglia, Giulia Quaresmini, Paolo Rivela, Gianluca Gaidano, Mauro Krampera, Luca Laurenti, Alessandro Rambaldi, Benedetto Bruno, Candida Vitale, Marta Coscia","doi":"10.1111/bjh.19976","DOIUrl":"10.1111/bjh.19976","url":null,"abstract":"<p>Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains an option for young and fit chronic lymphocytic leukaemia (CLL) patients with high-risk disease features. However, allotransplanted patients are generally excluded from clinical trials, making data regarding the use of venetoclax after alloHSCT extremely rare. We report data from 7 CLL patients who received venetoclax after alloHSCT among 53 Italian centers. These patients underwent alloHSCT between 2006 and 2021 after failing chemoimmunotherapy (7/7), ibrutinib (5/7) and/or idelalisib (1/7). Of note, 3/7 patients had already received venetoclax-based therapy before alloHSCT. Post-allo HSCT venetoclax treatment resulted safe, with adverse events not different from what reported in clinical trials. Importantly, no meaningful impact on graft versus host disease (GvHD) course was observed: 4/7 patients with pre-existing chronic GvHD had no exacerbation after venetoclax start, and only one patient developed GvHD during venetoclax therapy, that was managed as per standard clinical practice. Concerning efficacy, 5/7 patients presented a clinical response to venetoclax, with two patients achieving an undetectable minimal residual disease. To our knowledge, this is the largest reported series of CLL patients treated with venetoclax after alloHSCT. In these heavily pretreated and high-risk patients, previous alloHSCT did not compromise the feasibility of venetoclax therapy, that lacked unexpected toxicities and did not exacerbate GvHD.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 3","pages":"924-929"},"PeriodicalIF":5.1,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19976","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrea Serafin, Valeria Ruocco, Alessandro Cellini, Francesco Angotzi, Laura Bonaldi, Livio Trentin, Andrea Visentin
{"title":"Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype","authors":"Andrea Serafin, Valeria Ruocco, Alessandro Cellini, Francesco Angotzi, Laura Bonaldi, Livio Trentin, Andrea Visentin","doi":"10.1111/bjh.19986","DOIUrl":"https://doi.org/10.1111/bjh.19986","url":null,"abstract":"<p>Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease characterised by the uncontrolled proliferation of mature lymphocytes. A subset of CLL patients harbouring complex karyotype (CK) presents with poor prognosis and limited treatment options. This review aims to discuss the current understanding of such patient subset, including its molecular landscape, diagnostic approaches, treatment modalities and emerging therapies. Furthermore, it outlines strategies for personalised management to improve clinical outcomes in this challenging patient population.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 3","pages":"832-841"},"PeriodicalIF":5.1,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19986","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143564886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shiliang Ge, Saif Ali, Victoria Haldane, Carine Bekdache, Grace H. Tang, Michelle Sholzberg
{"title":"An approach to Hemequity: Identifying the barriers and facilitators of iron deficiency reduction strategies in low- to middle-income countries","authors":"Shiliang Ge, Saif Ali, Victoria Haldane, Carine Bekdache, Grace H. Tang, Michelle Sholzberg","doi":"10.1111/bjh.19984","DOIUrl":"10.1111/bjh.19984","url":null,"abstract":"<p>Approximately 1.92 billion people worldwide are anaemic, and iron deficiency is the most common cause. Iron deficiency anaemia (IDA) disproportionately affects women of reproductive age and remains under-addressed in low- to middle-income countries (LMICs). The primary objective of our scoping review is to evaluate the barriers and facilitators to IDA management in LMICs by using an intersectionality-enhanced implementation science lens adapted from the consolidated framework for implementation research and the theoretical domains framework. A total of 53 studies were identified. Contextual barriers included the deprioritization of IDA risk, unequal gender norms and stigma from the HIV/AIDS epidemic. Regional poverty, conflict and natural disasters led to supply chain barriers. Individual-level facilitators included partner support and antenatal care access while barriers included forgetfulness and having medical comorbidities. Successful interventions also utilized education initiatives to empower women in community decision-making. Moreover, community mobilization and the degree of community ownership determined the sustainability of IDA reduction strategies. IDA is not only a medical problem, but one that is rooted in the sociocultural and political context. Future approaches must recognize the resilience of LMIC communities and acknowledge the importance of knowledge translation rooted in community ownership and empowerment.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 2","pages":"428-442"},"PeriodicalIF":5.1,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19984","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells","authors":"Zhaozhao Chen, Anqi Ren, Yingying Li, Jinhui Shu, Jianghua Wu, Hekuan Huang, Jingming Wang, Yu Hu, Heng Mei","doi":"10.1111/bjh.19988","DOIUrl":"10.1111/bjh.19988","url":null,"abstract":"<p>Chimeric antigen receptor T-cell (CAR-T) therapy has shown transformative potential in treating malignant tumours, with increasing global approval of CAR-T products. However, high-production costs and risks associated with viral vector-based CAR-T cells—such as insertional mutagenesis and secondary tumour formation—remain challenges. Our study introduces an innovative CAR-T engineering approach using mRNA delivered via lipid nanoparticles (LNPs), aiming to reduce costs and enhance safety while maintaining strong anti-tumour efficacy. We developed an LNP-based transfection protocol for efficient delivery of mRNA encoding full-human CAR constructs, achieving high CAR expression and significant cytotoxicity against leukaemic cells in vitro. Co-culture with Raji cells showed increased cytokine secretion and tumour cell killing by mRNA-LNP CAR-T cells. Therapeutic efficacy was further demonstrated in an NOD-scid-IL2Rγnull (NSG) mouse model with Raji engraftment, where treated mice exhibited marked tumour regression and extended survival. These findings underscore the potential of mRNA-LNPs as a non-viral, effective CAR-T engineering platform, offering a promising alternative to traditional methods that could improve CAR-T safety, efficacy and accessibility in clinical cancer immunotherapy.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 2","pages":"628-643"},"PeriodicalIF":5.1,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19988","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Long-term efficacy and safety of avatrombopag in Chinese children with primary immune thrombocytopenia: A real-world observational study","authors":"Nan Wang, Zhifa Wang, Jingjing Liu, Yu Hu, Shuyue Dong, Hui Chen, Jinxi Meng, Jingyao Ma, Zhenping Chen, Xiaoling Cheng, Runhui Wu","doi":"10.1111/bjh.19973","DOIUrl":"10.1111/bjh.19973","url":null,"abstract":"<div>\u0000 \u0000 <p>Avatrombopag is a newly approved thrombopoietin receptor agonist for second-line treatment of chronic immune thrombocytopenia (ITP) in adults. Our previous study showed its efficacy and safety in a small sample of paediatric ITP patients. However, large samples and long-term data are still lacking. Children diagnosed with ITP and treated with avatrombopag for at least 4 weeks were enrolled. In 94 ITP patients with a median age of 7.43 (interquartile range (IQR), 4.82, 10.80) years, the median effective dose was 10 (IQR, 10, 20) mg for children under 6 years old and 20 (IQR, 20, 40) mg for children under 18 years old. The overall response was achieved in 72.3% (68/94) and 73.4% (58/79) of patients within 4 weeks and 12 weeks. The sustained response at 24 weeks and 48 weeks were 62.3% (33/53) and 51.6% (16/31) respectively. The occurrence of bleeding events, rescue therapy and concomitant ITP medication decreased during the follow-up period. For safety, thrombocytosis (platelet count ≥400 × 10<sup>9</sup>/L) was the most frequent adverse event (AE) observed in 44 children 97 times. Long-term treatment with avatrombopag in ITP children showed a rapid and sustained platelet response and good bleeding control without significant or new AEs.</p>\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 3","pages":"935-943"},"PeriodicalIF":5.1,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}